On August 5, shares of Israel-based drug discovery firm Compugen (NASDAQ:CGEN) popped ~45% in response to its disclosure of a potentially lucrative collaboration agreement with Bayer. CGEN will receive an upfront payment of $10M and potentially as much as $530M based on the achievement of certain milestones relative to the commercial development of two of CGEN's immune checkpoint regulators, CGEN-15001T and CGEN-15022. Upon regulatory clearance, CGEN will receive high single-digit royalties on global net sales. The contract has the potential to be CGEN's largest (by far) in its 20-year corporate life and deliver a profound fundamental boost to the firm considering its miniscule revenues of ~$600k (NYSE:TTM).
It doesn't take much scrutiny, though, to see that...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|